About US
Contact us
-
Don't count Merck's Keytruda out in lung cancer fight with BMS' OpdivoThose following the checkpoint inhibitor battle between Bristol-Myers Squibb's ($BMY)Opdivoand Merck's ($MRK)Keytruda--particularly in the lung cancer arena--know that industry watchers largely expect2015/9/29
-
Sanofi patent deal lets Lilly roll out a Lantus biosim in U.S. next DecemberSettlement covers SoloSTAR pen version, with more than 60% of franchise sales Sanofi has put off one biosimilar threat to Lantus till the end of 2016. In a patent settlement announced on Monday, the2015/9/29
-
Roche is 'well placed' for U.S. pricing tussle, CEO saysWorried about how mounting pricing pushback will affect Roche ($RHHBY)? Don't be, CEO Severin Schwan told Swiss newspaperFinanz und Wirtschaft. "Pressure will rise on drugs that are less sophisticated2015/9/28
-
Novartis scores EU rec for blockbuster-to-be EntrestoNovartis ($NVS) has predicted that its launch of newlyFDA-approved heart failure medEntrestowould be its "most exciting" ever. And now, it's one step closer to bringing that excitement to Europe. The2015/9/28
-
BMJ points up 'wide variations' in quality of data for new FDA indicationsOne of pharma's key strategies for growing a drug's sales is expanding into bigger groups of patients. Sometimes new meds hit the market for small-scale--even rare--diseases and then win approval for2015/9/25
-
Roche's slick new office tower opens its doors at Basel HQPhase one of Roche's ($RHHBY) brand-new, enlarged Basel, Switzerland, HQ is now open, featuring a 41-story tower designed by local architects Herzog & de Meuron. The tower--which Pierre de Meuron2015/9/25
-
BMJ: New analysis shows increased suicide rates in teens taking GSK's PaxilGlaxoSmithKline ($GSK) has faced its fair share of scrutiny over a study of its antidepressantPaxilin teenagers, with some experts claiming that the company wrote off harmful side effects linked to th2015/9/24
-
Advera Health Analytics: Merck statins linked to more muscle side effects than rest of classStatins are tried-and-true moneymakers, but they also come with their own set of safety concerns. Cardiovascular problems linked to the meds are nothing new, and scientists recently highlighted potent2015/9/24
-
J&J faces Tylenol lobbying allegations in first case to go to trial over medJohnson & Johnson ($JNJ) is gearing up for the first trial over claims that it promoted its blockbuster painkillerTylenolwithout disclosing potentially dangerous side effects. And the company coul2015/9/23
-
Novo Nordisk strikes deal with Iran government to produce insulin pens in the countryNovo Nordisk ($NVO) will step up its operations in Iran, saying today it will build a €70 million ($78.1 million) plant to produce its FlexPen prefilled devices to better supply the country with its i2015/9/23